Patients with pretreatment leukoencephalopathy and older patients have more cognitive decline after whole brain radiotherapy
Matthew Chan(BC Cancer Agency), Alan Nichol(BC Cancer Agency), Brian Thiessen(Princess Margaret Hospital), David W. Ferguson, Elaine Ni Mhurchu, Ren Yuan(University of British Columbia), Michael McKenzie(Provincial Health Services Authority), Robert Olson(BC Cancer Agency), Lovedeep Gondara(BC Cancer Agency), Roy Ma(BC Cancer Agency), Nafisha Lalani(University of Toronto)
Cited by 12
Related Papers
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
|The Lancet|2019|1.9k
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
|Journal of Clinical Oncology|2020|1.3k
Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer
|International Journal of Radiation Oncology*Biology*Physics|2016|736
Volumetric Modulated Arc Therapy for Delivery of Prostate Radiotherapy: Comparison With Intensity-Modulated Radiotherapy and Three-Dimensional Conformal Radiotherapy
|International Journal of Radiation Oncology*Biology*Physics|2008|532